Claims

1. A 5-HT_6 receptor antagonist in combination with an acetylcholinesterase inhibitor for use in the treatment of a CNS disease wherein balance, gait or movement is impaired due to degeneration of or functional impairment in cholinergic neurons.

2. The 5-HT_6 receptor antagonist and the acetylcholinesterase inhibitor for use in the treatment according to claim 1, wherein the CNS disease is selected from the group consisting of Parkinson's disease, Lewy Body Dementia, Parasupranuclear Palsy and Multi Systems Atropy.

3. The 5-HT_6 receptor antagonist and the acetylcholinesterase inhibitor for use in the treatment according to any of claims 1 or 2, wherein the CNS disease is Parkinson's disease.

4. The 5-HT_6 receptor antagonist and the acetylcholinesterase inhibitor for use in the treatment according to claim 3, wherein the treatment of Parkinson's disease is selected from the group consisting of reducing falls in a patient with Parkinson's disease, improving low gait speed in a patient with Parkinson's disease, reducing movement stoppages in a patient with Parkinson's disease, reducing freezing gait in a patient with Parkinson's disease, and improving gait control in a patient with Parkinson's disease.

5. The 5-HT_6 receptor antagonist and the acetylcholinesterase inhibitor for use in the treatment according to any of claims 1 to 4, wherein said acetylcholinesterase inhibitor is selected from the group consisting of donepezil, rivastigmine and galantamine.

6. The 5-HT_6 receptor antagonist and the acetylcholinesterase inhibitor for use in the treatment according to any of claims 1 to 5, wherein said 5-HT_6 receptor antagonist is idalopirdine.

7. The 5-HT_6 receptor antagonist and the acetylcholinesterase inhibitor for use in the treatment according to any of claims 1 to 6, wherein, when the acetylcholinesterase

inhibitor is donepezil, the dose of donepezil is from 1 to 30 mg, such as from 5 to 23 mg; when the AChEI is galantamine, the dose is from 4 to 24 mg; and when the AChEI is rivastigmine, the dose of rivastigmine is from 1 to 20 mg.

8. The 5-HT_6 receptor antagonist and the acetylcholinesterase inhibitor for use in the treatment according to any of claims 1 to 7, wherein when the 5-HT_6 receptor antagonist is idalopirdine, the daily dose of idalopirdine is from 10 mg to 120 mg, such as from 10 mg to 100 mg, such as from 30 mg to 90 mg, such as from 30 mg to 60 mg.

9. The 5-HT_6 receptor antagonist and the acetylcholinesterase inhibitor for use in the treatment according to any of claims 1 to 8, wherein the 5-HT_6 receptor antagonist is idalopirdine and the acetylcholinesterase inhibitor is donepezil.

10. The 5-HT_6 receptor antagonist and the acetylcholinesterase inhibitor for use in the treatment according to any of claims 4 to 9, wherein the treatment is for reducing falls in a patient with Parkinson's disease.

11. The 5-HT_6 receptor antagonist and the acetylcholinesterase inhibitor for use in the treatment according to any of claims 4 to 9, wherein the treatment is for improving low gait speed in a patient with Parkinson's disease.

12. The 5-HT_6 receptor antagonist and the acetylcholinesterase inhibitor for use in the treatment according to any of claims 4 to 9, wherein the treatment is for reducing movement stoppages in a patient with Parkinson's disease.

13. The 5-HT_6 receptor antagonist and the acetylcholinesterase inhibitor for use in the treatment according to any of claims 4 to 9, wherein the treatment is for reducing freezing gait in a patient with Parkinson's disease.

14. The 5-HT_6 receptor antagonist and the acetylcholinesterase inhibitor for use in the treatment according to claim 13, wherein the freezing gait is of less than about 2 seconds.

15. The 5-HT_6 receptor antagonist and the acetylcholinesterase inhibitor for use in the treatment according to any of claims 4 to 9, wherein the treatment is for improving gait control in a patient with Parkinson's disease.

16. The 5-HT_6 receptor antagonist and the acetylcholinesterase inhibitor for use in the treatment according to any of preceeding claims wherein the 5-HT_6 receptor antagonist is N-(2-(6-fluoro-1H-indol-3-yl)ethyl)-3-(2,2,3,3-tetrafluoropropoxy) benzylamine (idalopirdine).

17. The 5-HT_6 receptor antagonist and the acetylcholinesterase inhibitor for use in the treatment according to any of claims wherein the 5-HT_6 receptor antagonist is N-(2-(6-fluoro-1H-indol-3-yl)ethyl)-3-(2,2,3,3-tetrafluoropropoxy) benzylamine (idalopirdine) and the acetyl cholinesterase inhibitor is donepezil.